Guided Therapeutics (GTHP) Accounts Payables (2010 - 2026)

Guided Therapeutics has disclosed Accounts Payables across 17 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 4.08% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $2.3 million (up 4.08% YoY), while the FY2025 annual figure was $2.4 million, up 15.38% from the prior year.
• Accounts Payables came in at $2.3 million for Q2 2026 at Guided Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.5 million in Q1 2022 to a low of $1.9 million in Q1 2024.
• Average Accounts Payables over 5 years is $2.2 million, with a median of $2.2 million recorded in 2022.
• Year-over-year, Accounts Payables fell 12.19% in 2024 and gained 15.38% in 2025.
• Over 5 years, Accounts Payables stood at $2.2 million in 2022, then dropped by 8.92% to $2.0 million in 2023, then increased by 5.17% to $2.1 million in 2024, then grew by 15.38% to $2.4 million in 2025, then declined by 2.86% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.3 million in Q2 2026, $2.3 million in Q1 2026, and $2.4 million in Q4 2025.